Item 7.01 Regulation FD Disclosure.
On December 14, 2021, Galera Therapeutics, Inc. (the "Company" or "Galera") issued a press release announcing corrected topline results from the Phase 3 ROMAN trial of avasopasem manganese for severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy (the "ROMAN trial"), topline results from a single-arm Phase 2a trial of avasopasem in Europe, and certain other regulatory developments. A copy of the press release is furnished as Exhibit 99.1 hereto.
On December 14, 2021, the Company posted an updated corporate slide presentation in the "Investors" portion of its website at www.galeratx.com to accompany the conference call the Company will hold at 8:30 a.m. ET on December 14, 2021. A copy of that corporate slide presentation is attached to this Current Report on Form 8-K ("Form 8-K") as Exhibit 99.2. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2.
The information contained in Item 7.01 of this Form 8-K (including Exhibit 99.1 and Exhibit 99.2 attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly provided by...
Read Full Story: https://www.marketscreener.com/quote/stock/GALERA-THERAPEUTICS-INC-73950589/news/GALERA-THERAPEUTICS-INC-Regulation-FD-Disclosure-Other-Events-Financial-Statements-and-Exhibit-37312875/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.